[424B5] Catheter Precision, Inc. Prospectus Supplement (Debt Securities)
Rhea-AI Filing Summary
Catheter Precision, Inc. (NYSE American: VTAK) is updating its at-the-market (ATM) program. The new prospectus supplement limits additional issuances to $1.53 million of common stock that may be sold through Ladenburg Thalmann.
Key figures:
- Shares already sold: 8,649,526 for gross proceeds of $2.73 million during the last 12 months.
- Current public float: 21,336,987 shares worth $12.8 million (calculated at $0.60, the highest close in the past 60 days).
- Form S-3 Rule I.B.6 cap: While float remains below $75 million, VTAK may sell only one-third of its float every 12 months; $1.53 million capacity remains after prior sales.
- Recent market price: $0.17 per share on 4 Aug 2025, far below the float-calculation price.
Should the float rise—or exceed $75 million—the company may expand the program and will file another supplement. Prospective investors are urged to review the incorporated “Risk Factors,” particularly potential dilution and price pressure from continued share sales.
Positive
- Maintains access to an established ATM facility, offering flexible, low-cost capital raising when needed.
- Regulatory compliance with Form S-3 I.B.6 demonstrates governance discipline and transparency.
Negative
- Dilution risk: Additional $1.53 m issuance at ~$0.17 could expand share count by roughly 9 m shares.
- Limited proceeds: Remaining capacity is modest relative to financing needs, highlighting constrained liquidity.
- Weak share price: 72% drop from $0.60 reference price to $0.17 may pressure further sales and investor sentiment.
Insights
TL;DR: Small-cap ATM reset allows only $1.53 m of new stock; dilution risk high, financing flexibility modest.
The filing clarifies the remaining headroom under Rule I.B.6. VTAK has already tapped $2.73 m and can issue just $1.53 m more—about 12% of current float at the recent $0.17 price. While the supplement keeps the shelf alive, proceeds are unlikely to materially extend runway, and frequent low-priced sales could further depress the stock. Unless float grows above $75 m, capital-raising capacity stays constrained. Overall impact skews negative due to dilution and limited cash benefit.
TL;DR: Filing is largely procedural; limited cash raise tempers dilution but offers liquidity option.
The company preserves access to quick financing without an underwritten deal. Although the ceiling is low, any capital may bridge near-term needs. The amendment signals governance compliance and positions VTAK to scale sales if market cap improves. For now, the effect on valuation is neutral; investors should monitor usage rate and future float changes.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-284217
PROSPECTUS SUPPLEMENT
To Prospectus Supplement dated May 19, 2025
(To Prospectus dated January 22, 2025)
Up to $1,534,372
Common Stock
This prospectus supplement (the “Prospectus Supplement”) amends and supplements certain information in the prospectus supplement, dated May 19, 2025, to the prospectus dated January 22, 2025, filed with the Securities and Exchange Commission as part of our registration statement on Form S-3 (333-284217), (collectively, the “ATM Prospectus”), relating to the offer and sale of shares of our common stock from time to time pursuant to the terms of the At The Market Offering Agreement, dated May 19, 2025 (the “Agreement”), with Ladenburg Thalmann & Co. Inc. (“Ladenburg”) as sales agent. During the twelve calendar months prior to, and including, the date hereof, we have sold an aggregate of 8,649,526 shares of our common stock for aggregate gross proceeds of approximately $2,733,025 through Ladenburg under the Agreement. This Prospectus Supplement should be read in conjunction with the ATM Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the ATM Prospectus, and any future amendments or supplements thereto. This Prospectus Supplement supersedes and replaces the prospectus supplement dated June 13, 2025.
As of the date of this Prospectus Supplement, the aggregate market value of our common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $12,802,192, which was calculated based on 21,336,987 shares of our outstanding common stock held by non-affiliates and a price of $0.60 per share, the closing price of our common stock on June 11, 2025, which is the highest closing sale price of our common stock on the NYSE American within the prior 60 days. As of the date of this Prospectus Supplement, we have sold securities with an aggregate market value of approximately $2,733,025 pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of this Prospectus Supplement. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary offerings on Form S-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.6) in any 12-calendar month period so long as our public float remains below $75.0 million.
We are filing this Prospectus Supplement to amend the ATM Prospectus to update the maximum amount of shares that we are eligible to sell from and after the date hereof, and to specify the value of common stock we would be permitted to sell in any 12-calendar month period under General Instruction I.B.6. We may currently only offer and sell shares of our common stock having an aggregate offering price of up to $1,534,372 pursuant to this Prospectus Supplement in accordance with the terms of the Agreement, and as a result of the limitations set forth in General Instruction I.B.6. However, in the event that our public float increases or decreases, we may sell securities in public primary offerings on Form S-3 with a value up to one-third of our public float, in each case calculated pursuant to General Instruction I.B.6 and subject to the terms of the Agreement. In the event that our public float increases above $75.0 million, we will no longer be subject to the limits in General Instruction I.B.6 of Form S-3. If our public float increases such that we may sell additional amounts under the Agreement and the registration statement of which this Prospectus Supplement and the ATM Prospectus are a part, we will file another prospectus supplement prior to making additional sales.
Our common stock trades on the NYSE American under the symbol “VTAK.” On August 4, 2025, the last reported sale price of our common stock on the NYSE American was $0.17 per share.
Investing in our common stock involves a high degree of risk. Please read “Risk Factors” beginning on page S-3 of the ATM Prospectus and contained in the documents incorporated by reference into this Prospectus Supplement and the ATM Prospectus for a discussion of the factors you should carefully consider before deciding to purchase our common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Ladenburg Thalmann & Co. Inc.
Prospectus Supplement dated August 7, 2025
FAQ
How much stock can VTAK still sell under this prospectus supplement?
How many shares has VTAK already sold via the ATM?
Why is VTAK limited to one-third of its public float?
What is VTAK’s current public float?
What was the last reported share price for VTAK?
What happens if VTAK’s public float exceeds $75 million?
